| pubmed-article:18094221 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18094221 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:18094221 | lifeskim:mentions | umls-concept:C0242643 | lld:lifeskim |
| pubmed-article:18094221 | lifeskim:mentions | umls-concept:C0035608 | lld:lifeskim |
| pubmed-article:18094221 | lifeskim:mentions | umls-concept:C0059563 | lld:lifeskim |
| pubmed-article:18094221 | lifeskim:mentions | umls-concept:C0073393 | lld:lifeskim |
| pubmed-article:18094221 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:18094221 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:18094221 | pubmed:dateCreated | 2007-12-20 | lld:pubmed |
| pubmed-article:18094221 | pubmed:abstractText | The authors studied the effect of rifampin, a dual inducer of CYP3A and P-glycoprotein, on the pharmacokinetics and pharmacodynamics of risperidone in humans. Ten healthy male subjects were treated daily for 7 days with 600 mg rifampin or with placebo. On day 6, a single dose of 1 mg risperidone was administered. Plasma risperidone and 9-hydroxyrisperidone concentrations were measured. Rifampin significantly decreased the mean area under the plasma concentration-time curve by 51% for risperidone, by 43% for 9-hydroxyrisperidone, and by 45% for the active moieties (risperidone + 9-hydroxyrisperidone). Rifampin also decreased the peak plasma concentration of risperidone by 38%, 9-hydroxyrisperidone by 46%, and the active moieties by 41%. The apparent oral clearance of risperidone approximately doubled after rifampin treatment. Thus, rifampin reduced the exposure to risperidone, probably because of a decrease in its bioavailability through the induction of CYP3A and probably P-glycoprotein. | lld:pubmed |
| pubmed-article:18094221 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18094221 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18094221 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18094221 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18094221 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18094221 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18094221 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18094221 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18094221 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18094221 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18094221 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18094221 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18094221 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:18094221 | pubmed:issn | 0091-2700 | lld:pubmed |
| pubmed-article:18094221 | pubmed:author | pubmed-author:LiuKwang-Hyeo... | lld:pubmed |
| pubmed-article:18094221 | pubmed:author | pubmed-author:KimKyoung-AhK... | lld:pubmed |
| pubmed-article:18094221 | pubmed:author | pubmed-author:ParkJi-YoungJ... | lld:pubmed |
| pubmed-article:18094221 | pubmed:author | pubmed-author:ShinJae-GookJ... | lld:pubmed |
| pubmed-article:18094221 | pubmed:author | pubmed-author:LeeHeon-Jeong... | lld:pubmed |
| pubmed-article:18094221 | pubmed:author | pubmed-author:ParkPil-WhanP... | lld:pubmed |
| pubmed-article:18094221 | pubmed:author | pubmed-author:KimKwon-BokKB | lld:pubmed |
| pubmed-article:18094221 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18094221 | pubmed:volume | 48 | lld:pubmed |
| pubmed-article:18094221 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18094221 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18094221 | pubmed:pagination | 66-72 | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:meshHeading | pubmed-meshheading:18094221... | lld:pubmed |
| pubmed-article:18094221 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18094221 | pubmed:articleTitle | Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. | lld:pubmed |
| pubmed-article:18094221 | pubmed:affiliation | Department of Clinical Pharmacology & Toxicology, Anam Hospital, Korea University College of Medicine, 126-1, Anam-dong 5-ga, Sungbuk-gu, Seoul 136-705, Korea. | lld:pubmed |
| pubmed-article:18094221 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18094221 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:18094221 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
